华海药业(600521) - 2025 Q2 - 季度业绩预告

Zhejiang Huahai Pharmaceutical Co., Ltd. 2025 Semi-Annual Performance Pre-announcement of Decline Current Period Performance Forecast The company expects a significant decline in its 2025 first-half performance, with net profit attributable to shareholders projected to decrease by approximately 40% to 50% year-on-year, while net profit after deducting non-recurring gains and losses is expected to decline by about 45% to 55% year-on-year 2025 Semi-Annual Performance Forecast (RMB) | Performance Indicator | 2025 Semi-Annual Estimated Amount (RMB) | Year-on-Year Change | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 374 million to 449 million yuan | Decrease of approximately 40% to 50% | | Net Profit After Deducting Non-Recurring Gains and Losses | 344 million to 421 million yuan | Decrease of approximately 45% to 55% | Prior Period Performance Overview The report provides 2024 prior period performance data as a benchmark, with net profit attributable to shareholders at 748.566 million yuan, net profit after deducting non-recurring gains and losses at 764.8527 million yuan, and earnings per share at 0.52 yuan 2024 Semi-Annual Performance (RMB) | Performance Indicator | 2024 Semi-Annual Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | 748.566 million yuan | | Net Profit After Deducting Non-Recurring Gains and Losses | 764.8527 million yuan | | Earnings Per Share | 0.52 yuan | Key Reasons for Current Period Performance Change The year-on-year decline in current period performance is primarily influenced by three factors: product price decreases due to domestic centralized procurement, industry competition, and tariff issues impacting sales revenue; a significant year-on-year increase in R&D investment to accelerate biological innovative drug projects; and reduced exchange gains due to foreign currency exchange rate fluctuations, while non-operating gains and losses increased year-on-year due to fair value changes in financial assets - Due to deepening domestic centralized procurement policies, intensified competition in the API industry, and the impact of China-US tariffs, the company's product prices continued to fall, leading to a year-on-year decrease in current period sales revenue[6] - The company accelerated the advancement of biological innovative drug R&D projects, resulting in a significant year-on-year increase in R&D investment[6] - Foreign currency exchange rate fluctuations led to a year-on-year decrease in exchange gains[6] - During the reporting period, non-operating gains and losses increased by approximately 50 million to 70 million yuan year-on-year, primarily due to increased gains from fair value changes in financial assets[6] Risk Warning The company confirms that there are currently no significant uncertainties affecting the accuracy of this performance forecast - The company states that there are no significant uncertainties affecting the accuracy of this performance forecast[7] Other Explanatory Notes The company explicitly states that the performance forecast data released this time is only a preliminary calculation result, unaudited, and the final accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report, reminding investors to be aware of investment risks - This performance forecast data is preliminary and unaudited by an accounting firm; the final data will be subject to the company's officially disclosed 2025 semi-annual report[8]